JPMorgan Trust I has recently filed a new prospectus for its U.S. Value Fund, which includes updated information on fees and expenses associated with various share classes. This filing is significant as it reflects the company's commitment to transparency and investor education in a competitive investment landscape.
The U.S. Value Fund aims to provide long-term capital growth, and the updated prospectus outlines the annual operating expenses for different share classes, including Class R2, Class R3, Class R4, Class R5, and Class R6. The management fees for these classes are set at 0.40%, with additional distribution fees varying by class.
The filing, dated October 27, 2026, also indicates that the fund's adviser has contractually agreed to waive fees and reimburse expenses to ensure that total annual fund operating expenses do not exceed specified limits. This proactive approach is designed to enhance the fund's attractiveness to potential investors.
Background
JPMorgan Trust I is an investment entity incorporated in Delaware. The company is known for its focus on mutual funds, particularly in the realm of value investing. The recent filing is part of a series of submissions made on the same day, indicating a busy period for the organization as it updates its offerings.
What the Filing Says
The prospectus outlines several key details, including:
"The Fund seeks to provide capital growth over the long-term."
It also specifies the annual operating expenses for each share class, which range from 0.49% to 1.25%, depending on the class. The document emphasizes the importance of understanding these costs before investing.
Impact
This update may affect current and potential investors in the U.S. Value Fund, as well as financial intermediaries who offer shares of the fund. The clarity provided in the prospectus could influence investment decisions and strategies among these groups.
What's Next
The filing does not say what happens next.
Read Next
Jacobson Mitchell Acquires Over 200,000 Shares of MSC Industrial
Sheila Gujrathi Files Form 3 as Bolt Biotherapeutics Updates Ownership
Wyndham Hotels board member reports stock transactions
Wyndham Hotels director Ronald L. Nelson reports stock trade
Alexandra A. Jung acquires shares in Wyndham Hotels & Resorts
Wyndham Hotels director acquires shares in recent transaction




